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Summary: The birth of a male baby was induced at 32 weeks. In utero, the child presented, inter alia, signs
of hydrops, hepatosplenomegaly and anaemia. Two in utero transfusions for correction of the anaemia were
performed at 28 and 29 weeks, respectively. The baby rapidly presented respiratory distress with mixed
acidosis. Three hours after birth, pink urine was excreted. Signs of icterus necessitated phototherapy, after
which photosensitivity occurred. Erythrocytes were fluorescent under long-wavelength UV light. The baby
died 24 hours after birth, displaying severe acidosis, a diffuse haemorrhagic syndrome, and repeated brady-
cardia which did not respond to isoprenaline.
The analysis of porphyrins in urine, blood and faeces of the baby gave the following results:
1) uroporphyrin (I and III isomeric series) was increased in urine and faeces, with traces in erythrocytes and
plasma;
2) heptacarboxyporphyrin I was found mainly in urine and much less in erythrocytes, plasma and faeces;
3) coproporphyrin I was increased in urine, erythrocytes, plasma and faeces, and
4) 5-aminolaevulinic acid and porphobilinogen in urine and plasma were within the reference ranges.
Determination of the enzymes of haem biosynthesis in erythrocytes and lymphocytes showed that both parents
possessed only 50% of the normal activity of cosynthase.
A previously described point mutation in codon 73 was observed in one parent. Fatal cases of neonatal
Günther^ disease are extremely rare and such an observation, according to our knowledge, is probably one
of the first described.
Introduction , . . . . . , ,
erythropoietic porphyna is characterized by an over-
Günther's disease, also called congenital erythropoi- production of porphyrins of isomer I series, with
etic porphyria (CEP), is a very rare (less than 200 accumulation of these compounds in bone marrow
cases reported) type of porphyria (1, 2). Congenital erythroblasts, teeth and bones (1,2). These porphyrins
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are excreted in excess in urine and faeces (1, 2).
Patients with congenital erythropoietic porphyria
show an inability to maintain the normal production
of porphyrins of isomer III type, consistent with di-
minished activity of uroporphyrinogen III synthase1)
(or cosynthetase or hydroxymethylbilane hydrolase
cyclizing, EC 3.2.1.75) (3). Congenital erythropoietic
porphyria is inherited as a Mendelian autosomal re-
cessive trait (4). The onset of the majority of cases
occurs before the 6th year of life and the main symp-
toms are cutaneous photosensitivity and haemolysis
(5). Congenital erythropoietic porphyria is very rarely
detected in utero or at birth (6, 7, 8).
Our patient is a male premature neonate. Birth was
induced at 32 weeks, because he presented in utero,
inter alia, signs of hydrops, hepatosplenomegaly and
anaemia. Two in utero transfusions for correction of
the anaemia were performed at 28 and 29 weeks,
respectively. The patient rapidly presented respiratory
distress with mixed acidosis.
t
Three hours after birth, pink urine was excreted. Signs
of icterus necessitated phototherapy, after which
marked photosensitivity occurred. Red blood cells
and bone marrow erythroblasts were fluorescent (red)
under long-wavelength UV light.
The baby died 24 h after birth, displaying severe
acidosis, a diffuse haemorrhagic syndrome, and re-
peated bradycardia which did not respond to isopren-
aline (Isuprel®).
This study describes the contribution of biochemical
investigations to the diagnosis of this rare type of
porphyria, associated with unusual clinical onset. We
also report the investigation of porphyrin metabolism
in the parents.
5-Aminolaevulinic acid dehydratase (EC 4.2.1.24)
Porphobilinogen dearainase (EC 4.2.1.75)
Uroporphyrinogen III cosynthase (EC 4.3.1.8)
Uroporphyrinogen decarboxylase (EC 4.1.1.37)
Coproporphyrinogen oxidase (EC 1.3.3.3)
Protoporphyrinogen oxidase (EC 1.3.3.4)
Materials and Methods
Urinary 5-aminolaevulinic acid and porphobilinogen were de-
termined spectrophotometrically after elution from ion-ex-
change resins (Bio-Rad, Germany), according to Mauzerall &
Granick (9).
Tab. 1. Erythrocyte porphyrins
Porphyrins
Uroporphyrin fraction
Octacarboxyporphyrin
Heptacarboxyporphyrin
Coproporphyrin fraction
Hexacarboxyporphyrin
Pentacarboxyporphyrin
Tetracarboxyporphyrin
Protoporphyrin fraction
Protoporphyrin
Zinc protoporphyrin
Isomer fractionation
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
Patient
traces
traces
traces
1715
ND
ND
1715
58
48
10
Father
32
32
ND
34
7
9
18
110
43
67
Mother
26
26
ND
71
10
8
53
163
141
22
Reference
values
< 50
<100
<500
Octacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Heptacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Hexacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Pentacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Tetracarboxyporphyrin
Isomer I (%)
Isomer III (%)
33
67
100
ND
ND
ND
ND
ND
95
5
40
60
ND
ND
100
ND
45
55
40
60
60
40
ND
ND
100
ND
ND
100
»
27
73
< 30
> 70
< 30
> 70
< 30
> 70
< 30
> 70
< 30
> 70
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Urinary and faecal porphyrins were determined by high per-
formance liquid chromatography (HPLC) as previously de-
scribed (9).
Plasma porphyrins were determined by HPLC, using a method
derived from that of Longas & Poh-Fiizpairick (10).
Erythrocyte porphyrins were determined by HPLC, using a
method derived from that of Scoble et al. (11).
Isomers I and III in urine, faeces, plasma and erythrocytes were
fractionated by HPLC, using a method derived from that of
Lim et al. (12).
Uroporphyrinogen III synthase activity in erythrocytes (both
parents) was determined as previously described (8).
5-Aminolaevulinate dehydratase (EC 4.2.1.24), porphobilino-
gen deaminase (EC 4.3.1.8) and uroporphyrinogen decarbox-
ylase (EC 4.1.1.37) activities1) were determined in erythrocytes
as previously described (9, 13).
Coproporphyrinogen oxidase (EC 1.3.3.3) and protoporphyri-
nogen oxidase (EC 1.3.3.4) activities1) were determined in lym-
phocytes as previously described (14, 15).
led us to a more detailed investigation of porphyrin
metabolism, including the fractionation of isomers I
and III, and determination of the enzymes of haem
biosynthesis. This study was performed on the patient
and his two parents.
Tables 1 to 4 present the results of porphyrin deter-
minations in plasma, erythrocytes, urine and faeces.
In the patient, tetracarboxyporphyrin (almost exclu-
sively isomer I) was strongly increased in erythrocytes,
plasma, urine and faeces. Octacarboxyporphyrin (a
mixture of isomers I and III) was strongly increased
in urine and to a lesser degree in faeces. Heptacar-
boxyporphyrin (isomer I) was increased in urine, and
to a lesser degree in plasma, erythrocytes and faeces.
Table 5 shows the results for several enzymes of haem
biosynthesis.
Results
Some features of the clinical investigation (emission
of pink urine, hirsutism, photosensitivity) and the
erythrocyte fluorescence under long-wavelength UV
Discussion
Although one of the rarest of the porphyrias, con-
genital erythropoietic porphyria was the first of these
diseases recorded in the literature, probably because
Tab. 2. Plasma porphyrins and precursors
5-Aminolaevulinic acid (μηιοΐ/l)
Porphobilinogen (μηιοΙ/1)
Uroporphyrin fraction
Octacarboxyporphyrin
Heptacarboxyporphyrin
Coproporphyrin fraction
Hexacarboxyporphyrin
Pen lacarboxy porphyrin
Tetracarboxyporphyrin
Protoporphyrin (nmol/1)
Isomer fractionation
Octacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Heptacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Hexacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Pent aca rboxyporphy rih
Isomer I (%)
Isomer III (%)
Tetracarboxyporphyrin
Isomer I (%)
Isomer III (%)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
(nmol/1)
Patient
not determined
not determined
6
traces
6
4053
ND
ND
4053
54
50
50
100
ND
ND
ND
ND
ND
100
ND
Father
0.1
0.1
traces
traces
ND
4
ND
4
ND
27
ND
100
ND
ND
ND
ND
ND
100
ND
ND
Mother
0.1
0.2
traces
traces
ND
12
ND
12
traces
41
50
50
ND
ND
ND
ND
35
65
100
ND
Reference
values
< 0.6
< 0.2
< 5
<10
<50
<30
>70
<30
>70
<30 .
>70
<30
>70
<30
>70
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Tab. 3. Urine porphyrins and precursors
5-Aminolaevulinic acid
(μηιοΐ/g creatinine)
Porphobilinogen
Patient.
26
ND
Father
8
1
Mother
10
1
Reference
values
< 25
< 5
(μηιοΐ/g creatinine)
Uroporphyrin fraction
(nmol/g creatinine)
Octacarboxyporphyrin
(nmol/g creatinine)
Heptacarboxyporphyrin
(nmol/g creatinine)
Coproporphyrin fraction
(nmol/g creatinine)
Hexacarboxyporphyrin
(nmol/g creatinine)
Pentacarboxyporphyrin
(nmol/g creatinine)
Tetracarboxypprphyrin
(nmol/g creatinine)
Isomer fractionation
Octacarboxyporphyrin
166539
154920
11619
266232
ND
18682
247549
31
31
ND
340
ND
ND
340
10
10
traces
386
ND
ND
386
<740
Isomer I (%)
Isomer III (%)
Heptacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Hexacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Pentacarboxyporphyrin
Isomer I (%)
Isomer III (%)
Tetracarboxyporphyrin
Isomer I (%)
Isomer III (%)
43
57
100
ND
ND
ND
100
ND
99
1
50
50
ND
ND
ND
ND
ND
ND
97
3
35
65
60
40
ND
ND
100
ND
45
55
< 30
> 70
< 30
> 70
< 30
> 70
< 30
> 70
< 30
> 70
of the severity of its cutaneous symptoms (16). Con-
genital erythropoietic porphyria is a very rare disease
(less than 200 cases reported in the literature). Higher
prevalences reported previously are explained by con-
fusion with early-onset cases of cutaneous hepatic
porphyria (17, 18, 19).
The pattern of porphyrin overproduction in congen-
ital erythropoietic porphyria indicates that the block
in the haem synthetic pathway occurs at the level of
uroporphyrinogen III synthase (3, 20-25). This en-
zyme catalyses the formation of uroporphyrinogen III
from hydroxymethylbilane or from porphobilinogen
if porphobilinogen deaminase is present (2). Patients
with congenital erythropoietic porphyria demonstrate
an inability to maintain the normal production of
series III isomers, consistent with a diminished activity
of uroporphyrinogen III synthase (3).
Erythrocyte uroporphyrinogen III synthase activity
in both parents of our patient is about 50% of the
normal value, which is compatible with an heterozy-
gous state for congenital erythropoietic porphyria
(26).
Although there is a deficiency of uroporphyrinogen
III synthase, it does not completely block the synthesis
of series III isomer porphyrins (1, 2). Indeed, as stated
previously, there is some increase in total porphyrin
synthesis, as evidenced by increased concentrations in
peripheral blood and urine (1, 2). In our patient, we
observed a large predominance of type-I isomers of
tetra; penta- and heptacarboxyporphyrins in all the
biological material examined (erythrocytes, plasma,
urine and faeces). The octacarTDoxyporphyrins were
detected in small amounts in erythrocytes, plasma
and faeces, and high quantities were excreted in urine.
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Tab. 4. Faecal porphyrins
Porphyrins Patient
Uroporphyrin fraction 22
(nmol/g dry weight)
Octacarboxyporphyrin 14
(nmol/g dry weight)
Heptacarboxyporphyrin 8
(nmol/g dry weight)
Coproporphyrin fraction 2132
(nmol/g dry weight)
Hexacarboxyporphyrin ND
(nmol/g dry weight)
Pen tacarboxy porphyrin 43
(nmol/g dry weight)
Tetracarboxyporphyrin 2089
(nmol/g dry weight)
Protoporphyrin 61
(nmol/g dry weight)
Isomer fractionation
Octacarboxyporphyrin
Isomer I (%) 35
Isomer III (%) 65
Heptacarboxyporphyrin
Isomer I (%) 100
Isomer III (%) ND
Hexacarboxyporphyrin
Isomer I {%) ND
Isomer III (%) ND
Pentacarboxyporphyrin
Isomer I (%) 100
Isomer 111 (%) ND
Tetracarboxyporphyrin
Isomer I (%) 100
Isomer III (%) ND
Father
3
1
2
34
ND
ND
34
1
65
35
ND
100
ND
ND
ND
ND
85
15
Mother
6
4
2
10
ND
ND
10
1
40
60
20
80
ND
ND
ND
ND
80
20
Reference
values
ND
<110
< 90
< 30
> 70
< 30
> 70
< 30
> 70
< 30
> 70
50-70
30-50
Tab. 5. Haem biosynthesis enzymes determination
Enzyme
Erythrocyte 5-aminolaevuiinate dehydratase
(5-aminolaevulinate, mol/min · 1 erythrocytes at 37 °C)
Erythrocyte porphobilinogen deaminase
(uroporphyrm, pmol/h · mg haemoglobin at 37 °C)
Erythrocyte uroporphyrinogen cosynthase
(cosynthase, units/ing protein at 37 °C)
Erythrocyte uroporphyrinogen decarboxylase
(coproporphyrinogen, nmol/h · mg protein at 37 °C)
Lymphocyte coproporphyrinogen oxidase
(protoporphyrin, pmol/mg protein at 37 °C)
Lymphocyte protoporphyrinogen oxidase
(protoporphyrin, nmol/h · mg protein at 37 °C)
Father
38
142
5.0
40
706
5.2
Mother
43
178
5.5
36
499
5.0
Reference
values
20 - 60
103 -243
8.0- 12.0
30 - 70
350 -650
3.6- 6.0
Eur. J. Clin. Chem. Clirt. Biochem. / Vol. 31,1993 / No. 3
126 Verstraeten et al.: Fatal case of Günthers disease in a newborn
In all these biological fluids, the ratio of isomer I to
isomer III varied from 30 to 50%.
Furthermore, increased concentrations of erythrocyte
porphyrins have been found in relatives of congenital
erythropoietic porphyria patients, consistent with a
partial deficiency of uroporphyrinogen III synthase
in heterozygotes (3, 27-29). In our study, plasma
and erythrocyte porphyrins were within reference
range for both parents. The patient showed extremely
high concentrations of plasma and erythrocyte copro-
porphyrin, almost exclusively of the type-I isomer.
Typically, the urinary total porphyrin concentration
in congenital erythropoietic porphyria is between
20000 and 90000 nmol/1 (2). This consists mainly of
uroporphyrin and heptacarboxylic porphyrin, with
10-20% coproporphyrin (30, 31). In our patient,
urine total porphyrin concentration was about
430000 nmol/1. Coproporphyrin (almost exclusively
type-I isomer) is predominant in urine. Both parents
have urine porphyrin values within the reference
range, but the father excretes predominantly type-I
coproporphyrin. It is to be noted that the copropor-
phyrin in normal urine consists of 70% isomer III
and 30% isomer I (32). An increased ratio of copro-
porphyrin I to coproporphyrin III may be observed
in other diseases such as cholestasis and Dubin-John-
son syndrome (33, 34). Excessive production of inter-
mediate porphyrins, as found by HPLC, also occurs
in cutaneous hepatic porphyria, but the pattern of
excreted compounds is quite different (1, 2). Isomeric
fractionation shows that more than 80% of the total
porphyrin is of series I, although, as stated before,
there is also an overall increase in the production and
excretion of uroporphyrinogen III (1, 2). Concerning
uroporphyrin, isomeric fractionation reveals a mix-
ture of isomers I and III in all samples examined,
whereas the typical pattern shows a predominance of
type-I isomers (1). The predominance of uroporphyrin
I over uroporphyrin III may also be observed in cases
of cutaneous hepatic porphyria (35).
Faecal porphyrins are usually elevated in congenital
erythropoietic porphyria, consisting predominantly of
coproporphyrin, with a variable, but usually slight
increase in protoporphyrin (1, 2). Uroporphyrin is
also normally detectable in the faeces (1, 2). Unlike
cutaneous hepatic porphyria, the isocoproporphyrin
series of porphyrins is not detected (1, 2). In our
patient, faecal coproporphyrin is strongly increased,
together with a mild increase of uroporphyrin, hepta-
and pentacarboxyporphyrins.
The strong increase of coproporphyrin in all biolog-
ical samples led us to consider the diagnosis of a
coexistent hereditary coproporphyria, an association
previously described in a young female patient (36).
This diagnosis was ruled out by the presence of nor-
mal values for lymphocyte coproporphyrinogen Oxi-
dase observed in both parents. The presence in all
biological samples examined (erythrocytes, plasma,
urine, faeces) of high concentrations of copropor-
phyrins, consisting of nearly 100% of the isomer I
series, also excluded the diagnosis of hereditary co-
proporphyria in our patient (1, 2).
Concerning differential diagnosis, the laboratory in-
vestigations must be used to exclude other forms of
porphyria, particularly any of the extremely rare cases
of homozygous porphyria, as found in cutaneous
hepatic porphyria and hereditary coproporphyria (1,
2). This diagnosis was excluded by the normal values
of uroporphyrinogen decarboxylase and copropor-
phyrinogen oxidase in both parents, together with
protoporphyrinogen oxidase.
With respect to the pathogenesis of cutaneous lesions
(major photosensitivity observed after phototherapy,
applied in this case because of icterus), many of the
features of congenital erythropoietic porphyria differ
only in severity from those found in other cutaneous
porphyrias, such as cutaneous hepatic porphyria (1,
2). Our patient shows moderate hirsutism, which is
commonly observed in cases of congenital erythro-
poietic porphyria (1, 2).
The majority of the patients presenting congenital
erythropoietic porphyria suffer from haemolytic anae-
mia (1, 2). In this case, anaemia (haemoglobin con-
centration: 72 g/1) was diagnosed at 28 weeks and was
treated by two in utero transfusions at 28 and 29
weeks. Indirect and direct Coomb's tests were nega-
tive. Haemolysis seems to be associated with an in-
creased osmotic fragility of erythrocytes, due to in-
creased concentrations of erythrocyte porphyrins (37).
Porphyrin deposition may also be found in bone
marrow (38), where between 30 and 70% of the eryth-
roblasts show porphyrin fluorescence (fluorocytes),
i.e. bright red fluorescence is observed under long-
wavelength UV light (38); this was also observed in
our case.
The patient showed marked hepatosplenomegaly. In
congenital erythropoietic porphyria, the liver in par-
ticular makes a significant contribution to excessive
porphyrin synthesis (39). Splenomegaly is always ob-
served in cases of congenital erythropoietic porphyria
(1, 2). There are no characteristic histological findings
in the spleen other than the manifestations of hae-
molysis (1^2). .;
Congenital erythropoietic porphyria is expressed very
rarely in utero, as is shown by the autopsy on a
Eur. J. din. Chem. Clin. Biochem. / Vol. 31,1993 / No. 3
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newborn child (40), by diagnosis at birth (6) and by
prenatal diagnosis (7, 8). Reddish-brown amniotic
fluid with an increased porphyrin content is usually
encountered early in the second trimester of preg-
nancy in fetuses with congenital erythropoietic por-
phyria (7, 41). In the present case, this fluid was
colourless.
One of the earliest signs of the disease may be the
excretion of reddish-coloured urine (1, 2). Emission
of pink urine after three hours of life, together with
a naso-pharyngal and gastric aspiration of pink liquid
was observed in our case.
The patient shows the criteria of neonatal congenital
erythropoietic porphyria, according to Schwartz:
1) emission of red urine together with an increase of
uroporphyrins and coproporphyrins and normal
concentrations of 5-aminolaevulinic acid and por-
phobilinogen;
2) presence of splenomegaly and haemolytic anaemia;
3) red fluorescence of the bone marrow (14).
Clinically, congenital erythropoietic porphyria may
be distinguished from early-onset cutaneous hepatic
porphyria by the presence of splenomegaly, erythro-
dontia (due to porphyrin accumulation in teeth, pa-
thognomonic of congenital erythropoietic porphyria),
anaemia and erythrocyte fluorescence (1, 2).
Congenital erythropoietic porphyria is inherited in an
autosomal recessive fashion (1, 2). In this family, both
parents are asymptomatic and heterozygous for con-
genital erythropoietic porphyria. Their first child was
in good health. The second child died in utero at 33
weeks under very similar conditions to those observed
in the present case (their third child): hydrops foetalis
with hepatosplenomegaly compatible with an hae-
molytic anaemia (Coomb's test was negative) and ex-
tramedullar erythropoiesis.
The isolation and sequencing of a full-length comple-
mentary DNA (cDNA) encoding uroporphyrinogen
III synthase allows the study of the enzymatic defect
at the molecular level (42). Different point mutations,
insertions or deletions have been detected (43 — 45).
It has now been shown that one of the parents carries
the C 73 R mutation (a cysteine replaced by an argi-
nine at position 73 in the protein), which has been
previously described (43).
Conclusion
A fatal case of Günthers disease (congenital ery-
thropoietic porphyria) is reported in a baby whose
birth was induced at 32 weeks. The biochemical di-
agnosis was made on the basis of:
1. a massive increase, in erythrocytes, plasma, urine
and faeces, of type-I porphyrins (mainly copro-
porphyrin);
2. a familial study revealing that both parents are
heterozygous for uroporphyrinogen III synthase
deficiency;
3. the observation of a point mutation in codon 73
in one parent.
Fatal cases of neonatal congenital erythropoietic por-
phyria are extremely rare and such an observation,
according to our knowledge, is probably one of the
first described.
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